Activating mutations in the epidermal growth factor receptor (EGFR) occur in approximately 40% of NSCLC cases 1,2, with exon 19 deletions (19Del) and the exon 21 L858R substitution representing the most frequent alterations 2. Here, EGFR is linked to non-small cell lung carcinoma.